Clinical evaluation investigates semaglutide efficacy and safety in heart failure with preserved ejection fraction and obesity, highlighting potential cardiovascular benefits.
Semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has shown promise in weight management and cardiovascular outcomes in other populations. This study aimed to evaluate the efficacy of semaglutide in heart failure with preserved ejection fraction (HFpEF) patients with obesity.
No takes yet. Share an insight, caveat, or question.
Rehman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: